Gongwin Biopharm Co., Ltd., a Taiwan-based clinical-stage biopharmaceutical company, is dedicated to developing innovative and effective anti-cancer drugs. Their unique approach involves a therapy called minimally-invasive targeted tumor ablation (MITTA), which combines the intratumoral injection of PTS (para-toluenesulfonamide) with minimally-invasive intervention. This approach offers several advantages, including targeted treatment of specific tumors and high selectivity for tumor cells.

Gongwin-KY has conducted a Phase III clinical trial in China, demonstrating the safety and efficacy of PTS MITTA therapy. Under their product pipeline, Gongwin-KY has several drug candidates in development. PTS302 targets lung cancer and has been granted special review for approval.

PTS100 focuses on liver cancer and has undergone Phase II clinical trials. PTS-02 targets Adenoid cystic carcinoma (ACC), and PTS500 is intended for the treatment of Malignant pleural effusion. In addition to anti-cancer drugs, Gongwin-KY is also working on other novel drugs to address unmet medical needs.

They are establishing a GMP-equivalent pilot laboratory to enhance their research and development capabilities. With a commitment to innovation, professionalism, integrity, and care, Gongwin-KY aims to provide high-quality and safe novel drugs to improve patient outcomes worldwide